Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Ocul Immunol Inflamm ; 30(5): 1218-1221, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1671883

ABSTRACT

METHOD: We report a case of bilateral panuveitis and its resolution based on multimodal retinal images after she was administered the first dose of a viral vector-based vaccine against SARS-CoV-2. CASE REPORT: A 72-year-old woman complained of bilateral blurred vision with headache, neck stiffness, and tinnitus 3 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Initial examination revealed anterior chamber reactions, left optic disc hyperemia, and bilateral chorioretinal folds with choroidal thickening. Fluorescein and indocyanine green angiography revealed bilateral choroiditis and papillitis. Systemic steroid therapy dramatically alleviated panuveitis and meningeal signs. No recurrence was noted until 3 months after discontinuation of steroids. CONCLUSIONS: Bilateral panuveitis mimicking Vogt-Koyanagi-Harada disease can develop shortly after the first dose of the ChAdOx1 nCoV-19 vaccine. Ophthalmologists should consider bilateral panuveitis as a presumed post-vaccination adverse event. Systemic steroid therapy may be effective for the nCoV-19 vaccine-associated panuveitis.


Subject(s)
COVID-19 Vaccines , COVID-19 , Panuveitis , Uveomeningoencephalitic Syndrome , Aged , Female , Humans , ChAdOx1 nCoV-19 , COVID-19 Vaccines/adverse effects , Fluorescein Angiography/methods , Fluoresceins/therapeutic use , Indocyanine Green , Panuveitis/chemically induced , Panuveitis/diagnosis , Panuveitis/drug therapy , SARS-CoV-2 , Uveomeningoencephalitic Syndrome/diagnosis , Uveomeningoencephalitic Syndrome/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL